NCT05382767

Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity

A Randomized, Double-blind, Active-controlled, Multicenter Phase I Trial to Investigate the Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: CKD Bio Corporation · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Multicenter, randomized, double-blind, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501A in Subjects with Post-stroke Upper Limb Spasticity

Conditions

• Post-stroke Upper Limb Spasticity

Interventions

Type	Name	Description
DRUG	CKDB-501A	Muscle Spasticity
DRUG	Botox®	Muscle Spasticity

Timeline

• Start date: 2022-06-02
• Primary completion: 2022-12-08
• Completion: 2022-12-08
• First posted: 2022-05-19
• Last updated: 2023-03-28

Locations

2 sites across 1 country: South Korea